PUMA BIOTECHNOLOGY INC
PBYI
PBYI: Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
moreShow PBYI Financials
Recent trades of PBYI by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PBYI's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
- $0 2023-04-18 00:00:00 Agency: Department of Veterans Affairs
- $15,769 2018-06-25 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $7,884 2018-04-23 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $7,884 2018-04-03 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $7,860 2018-03-06 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $7,860 2018-01-17 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Followers on PBYI's company Twitter account
Number of mentions of PBYI in WallStreetBets Daily Discussion
Recent insights relating to PBYI
Recent picks made for PBYI stock on CNBC
ETFs with the largest estimated holdings in PBYI
Flights by private jets registered to PBYI